The AAFP concludes that evidence is insufficient to recommend for or against routine screening for elevated blood lead levels in asymptomatic children aged 1 to 5 years who are at increased risk.
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
K-O: Recommendations for Clinical Preventive Services
Lead Poisoning
Lead Poisoning
The AAFP recommends against routine screening for elevated blood levels in asymptomatic pregnant women.
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Lead Poisoning
The AAFP recommends against routine screening for elevated blood levels in asymptomatic children aged 1 to 5 years who are at average risk.
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Lipid Disorders
The AAFP recommends screening men aged 35 and older for lipid disorders. (Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders
The AAFP recommends screening women aged 45 and older for lipid disorders if they are at increased risk for coronary heart disease.
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders
The AAFP recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for coronary heart disease.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders
The AAFP recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for coronary heart disease.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders
The AAFP makes no recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for coronary heart disease.
(Grade: C recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: C recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders
The AAFP concludes that the evidence is insufficient to recommend for or against routine screening for lipid disorders in infants, children, adolescents, or young adults (up to age 20).
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lung Cancer
The AAFP recommends against the use of chest X-ray and/or sputum cytology in asymptomatic persons for lung cancer screening.
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf/uspslung.htm
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf/uspslung.htm
Neural tube defects
The AAFP recommends that all women planning or capable of pregnancy take a daily supplement containing 0.43 to 0.8 mg (400 to 800 µg) of folic acid.
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Consideration: www.ahrq.gov/clinic/uspstf09/folicacid/folicacidrs.htm#clinical
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Consideration: www.ahrq.gov/clinic/uspstf09/folicacid/folicacidrs.htm#clinical
Obesity
The AAFP recommends that family physicians screen all adult patients for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss for obese adults. Intensive counseling involves more than one session per month for at least 3 months.
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsobes.htm
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsobes.htm
Obesity
Optimal weight management in children and adolescents is desirable. The effectiveness of screening and counseling for overweight is uncertain.
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf05/choverwt/choverrs.htm#clinical
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf05/choverwt/choverrs.htm#clinical
Oral Cancer
The AAFP concludes that the evidence is insufficient to recommend for or against routinely screening adults for oral cancer.
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsoral.htm
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsoral.htm
Osteoporosis
The AAFP recommends routinely screening women aged 65 and older for osteoporosis.
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Osteoporosis
The AAFP recommends routinely screening women aged 60 and older at increased risk for osteoporotic fractures.
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Osteoporosis
The AAFP recommends counseling females age 11 and older to maintain adequate calcium intake prevent osteoporosis.
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Ovarian Cancer
The AAFP recommends against routine screening for ovarian cancer.
Clinical Considerations: www.ahrq.gov/clinic/uspstf/uspsovar.htm
Clinical Considerations: www.ahrq.gov/clinic/uspstf/uspsovar.htm
Ovarian Cancer/BRCA Mutation Testing
The AAFP recommends that women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing.
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
Ovarian Cancer/BRCA Mutation Testing
The AAFP recommends against routine referral for genetic counseling or routine breast cancer susceptibility gene (BRCA) testing for women whose family history is not associated with increased risk for deleterious mutations in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2).
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
Clinical Preventive Services
AAFP Summary of Recommendations for Clinical Preventive Services Tool
K-O
Clinical Preventive Services (*PDF file)
(*PDF file. About PDFs)
